Susquehanna Fundamental Investments’s UroGen Pharma URGN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-62,809	Closed	-$695K	–	1016
2025 Q1	$695K	Buy	62,809 +43,268	+221%	+$461K	0.01%	770
2024 Q4	$208K	Buy	+19,541	New	+$234K	﹤0.01%	1002
2021 Q3	–	Sell	-21,831	Closed	-$333K	–	1906
2021 Q2	$333K	Buy	+21,831	New	+$395K	0.01%	1329

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Susquehanna Fundamental Investments's URGN Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 62,809 shares — an estimated $695K sold.

Susquehanna Fundamental Investments first reported a position in URGN in Q2 2021 and held it in 3 quarters. The position peaked at $695K in Q1 2025. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 62,809 UroGen Pharma shares in Q2 2025, an estimated $695K.
Susquehanna Fundamental Investments first reported a position in UroGen Pharma in Q2 2021 and held it in 3 quarters.
Susquehanna Fundamental Investments's UroGen Pharma position peaked at $695K in Q1 2025.
150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.